drugset / Trial / NCT04393675
Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
A Randomized, Double Blind, Placebo-Controlled study to assess the Safety, Local Tolerance, and Pharmacokinetics of LT5001 drug product in Hemodialysis Patients with Uremic Pruritus
Timeline
- Start
- 2020-05-14
- Primary completion
- 2022-09-15
- Completion
- 2022-09-15
Outcome
Outcome not reported
Stopped: “Change in the clinical development plan”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | LT5001 | Unknown | 6 g | — |
Indications
No indication recorded.